 CAMBRIDGE, Mass.--BUSINESS WIRE--Sage Therapeutics, Inc. NASDAQ: SAGE, a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the Company will participate in a fireside chat at Cowens Psychedelics Novel Mechanisms in Neuropsychiatry Summit on July 13th at 2:25pm ET. A live webcast of the presentation can be accessed on the investor page of Sages website at 